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Abstract
Background: Stromelysin-3 (ST-3) is over-expressed in the majority of human carcinomas including breast carcinoma.
Due to its known effect in promoting tumour formation, but its impeding effect on metastasis, a dual role of ST-3 in
tumour progression, depending on the cellular grade of dedifferentiation, was hypothesized.
Methods: The present study was designed to investigate the influence of ST-3 in vivo and in vitro on the oestrogen-
dependent, non-invasive MCF-7 breast carcinoma cell line as well as on the oestrogen-independent, invasive MDA-MB-
231 breast carcinoma cell line. Therefore an orthotopic human xenograft tumour model in nude mice, as well as a 3D
matrigel cell culture system, were employed.
Results: Using both in vitro and in vivo techniques, we have demonstrated that over-expression of ST-3 in MCF-7 and
MDA-MB-231 cells leads to both increased cell numbers and tumour volumes. This observation was dependent upon the
presence of growth factors. In particular, the enhanced proliferative capacity was in MCF-7/ST-3 completely and in MDA-
MB-231/ST-3 cells partially dependent on the IGF-1 signalling pathway. Microarray analysis of ST-3 over-expressing cells
revealed that in addition to cell proliferation, further biological processes seemed to be affected, such as cell motility and
stress response. The MAPK-pathway as well as the Wnt and PI3-kinase pathways, appear to also play a potential role.
Furthermore, we have demonstrated that breast cancer cell lines of different differentiation status, as well as the non-
tumourigenic cell line MCF-10A, have a comparable capability to induce endogenous ST-3 expression in fibroblasts.
Conclusion: These data reveal that ST-3 is capable of enhancing tumourigenesis in highly differentiated "early stage"
breast cancer cell lines as well as in further progressed breast cancer cell lines that have already undergone epithelial-
mesenchymal transition. We propose that ST-3 induction in tumour fibroblasts leads to the stimulation of the IGF-1R
pathway in carcinoma cells, thus enhancing their proliferative capacity. In addition, further different cellular processes
seem to be activated by ST-3, possibly accounting for the dual role of ST-3 in tumour progression and metastasis.
Published: 17 January 2007
BMC Cancer 2007, 7:12 doi:10.1186/1471-2407-7-12
Received: 11 October 2006
Accepted: 17 January 2007
This article is available from: http://www.biomedcentral.com/1471-2407/7/12
© 2007 Kasper et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2007, 7:12 http://www.biomedcentral.com/1471-2407/7/12
Page 2 of 12
(page number not for citation purposes)
Background
The human protein family of matrix metalloproteinases
(MMPs) includes at least 25 members that are believed to
play a role in the various stages of tumourigenesis [1,2].
Most of these zinc-dependent endopeptidases cleave
more than one extracellular matrix (ECM) component
and each ECM component is generally cleaved by more
than one MMP. Aside from matrix degradation, MMPs
play an important role in releasing growth factors, such as
TGF-β or VEGF, or other biologically active factors [3,4].
The effect of over-expression or inhibition of MMPs in
tumours might be complex, as these proteases are able to
promote and impede tumour relevant processes such as
proliferation, apoptosis, angiogenesis and metastasis [5].
Stromelysin-3 (ST-3, MMP-11) was originally identified
as a breast cancer associated gene, which is over-expressed
in more than 90% of invasive breast carcinomas [6].
Recent studies have shown that ST-3 over-expression is
found in most human carcinomas [7]. Expression of the
gene has also been detected in fibroblasts at the invasion
front of tumours in close proximity to carcinoma cells [6].
Furthermore, it has been shown that ST-3 expression is
induced in fibroblasts by co-culturing with breast carci-
noma cells [8,9]. Although ST-3 was discovered more than
a decade ago and assigned to the family of MMPs due to
sequence homologies, no ECM component has yet been
identified that is cleaved by full length human ST-3 [10].
However, ST-3 has been found to cleave IGFBP-1, thereby
releasing IGF-1 [11]. IGF-1 is known to stimulate prolifer-
ation, enhancing survival and migration of cancer cells
[12]. Despite a limited knowledge of ST-3 substrates and
mode of action, an in vitro study has demonstrated that
ST-3 over-expression in MCF-7 cells is capable of increas-
ing cell survival under serum starvation conditions [13].
However, the mechanism of ST-3  activation during
tumourigenesis remains unclear. Various in vivo studies
reveal a ST-3 specific function in tumourigenesis e.g. ST-3
enhanced tumour take of MCF-7 cells in nude mice when
injected subcutaneously [14]. Other studies, performed in
an ST-3 knock out mouse model and in human xenograft
models of ST-3 over-expressing MCF-7 cells demonstrate
that the activation of ST-3 leads to a lower percentage of
apoptotic cells in the induced tumours [15,16]. According
to these results, the generation of MMTV-ras transgenic
mice in an ST-3 deficient genotype results in the develop-
ment of less and smaller primary tumours [17]. Interest-
ingly, these mice developed more lung metastases. The
question has therefore arisen, whether ST-3 over-expres-
sion may cause different functional effects in different
stages of tumourigenesis and thereby play a dual role
[17,18], or whether compensation by other MMP family
members could account for the observed effect. Indeed, it
has been shown that during involution, ST-1 and ST-2 is
up-regulated in matrilysin knock out mice, and that mat-
rilysin and ST-2 expression is elevated in ST-1 deficient
mice [19].
In the present study, the influence of ST-3 on cell lines of
different stages of breast cancer progression is investi-
gated. To this end, the induction of endogenous ST-3
expression and the effect of ST-3 over-expression on the
non-invasive cell line MCF-7 as well as on the highly inva-
sive and dedifferentiated cell line MDA-MB-231 is ana-
lysed both in vitro and in vivo. Furthermore, the impact of
ST-3 over-expression on the gene expression pattern of
breast cancer cells was determined.
Methods
Cell culture
Primary fibroblasts were isolated from human breast
tumours (kindly provided by Dr. Têtu, Centre Hospitalier
Universitaire de Quebec, Canada)[8]. MDA-MB-231 cells
and primary breast tumour fibroblasts were maintained in
DMEM/F12. MCF-7 cells were maintained in RPMI w/o
phenol red (Gibco, Germany) supplemented with 0.002
U/ml insulin and 0.1 nM Estradiol (E2). For MDA-MB-
468, RPMI 1640 (Gibco, Germany) was used. These
media contained 10% FCS. MCF-10A cells were main-
tained in DMEM/F12 (Gibco, Germany) with 5% heat
inactivated horse serum, 20 ng/ml EGF, 100 ng/ml chol-
era toxin, 0.002 U/ml insulin and 500 ng/ml hydrocorti-
sone. For 3D matrigel cultures, 96 well plates were pre-
coated with matrigel (BD Bioscience, 10 mg/ml). 75 μl of
a cell/matrigel suspension containing 1 × 103 cells/μl were
added to each well. For co-cultures, 1 × 104 fibroblasts
were seeded on cover slips. When the cells reached conflu-
ence, epithelial cells were seeded on top. At day three, co-
cultures were incubated with 10 μg/ml Brefeldin A for 5
hours and investigated by immunocytochemistry.
Immunocytochemistry/Immunohistochemistry
Immunocytochemistry was carried out as described previ-
ously [20]. Briefly, cells grown on cover slips were washed
with PBS, fixed with 4% PFA and permeabilized in 0.2%
Triton-X100/PBS. Cover slips were incubated with the pri-
mary and, after washing, with the secondary antibodies
for 20 min at RT. For immunohistochemical staining, par-
affin sections were dewaxed and dehydrated by graded
ethanol. After blocking, sections were incubated with the
primary and secondary antibodies. As primary antibodies
goat α-(human vimentin) (1:30, Santa Cruz, Germany),
rabbit α-(human cytokeratin) (1:100, Novocastra, New-
castle) and mouse α-(human ST-3) (1:50, Clone SL3.05,
Neomarkers, CA) were used. Secondary antibodies were
donkey-α-(mouse IgG) Rhodamin Red (1:100, Dianova,
Germany) and donkey α-(goat IgG)Cy5 (1:400, Dianova,
Germany). Stainings were performed as triple stainings on
the same section. Samples were examined using a Leica
TCS SL confocal microscope (Leica, Germany).BMC Cancer 2007, 7:12 http://www.biomedcentral.com/1471-2407/7/12
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Generation of ST-3 over-expressing clones
ST-3 cDNA was amplified by performing a PCR and clon-
ing into the mammalian expression vector
pcDNA3.1V5HisTOPO (Invitrogen, Karlsruhe, Germany).
Expression of ST-3 protein was confirmed by in vitro tran-
scription/translation in reticulocyte lysate (Promega). The
ST-3 or empty expression plasmid was transfected into
MCF-7 and MDA-MB-231 cells. 6 μl Fugene (Boehringer,
Mannheim, Germany) was mixed with 196 μl Optimem
(Gibco, Karlsruhe, Germany) and incubated for 5 min at
room temperature. After supplementation with 2 μg DNA
and a further incubation period of 15 min, this mixture
was applied to a 60% confluent 6-well plate. On the fol-
lowing day, transfected cells were seeded at a density of
4000 cells/cm2 and selected by supplementation of media
with G418 (750 μg/ml for MDA-MB-231 and 600 μg/ml
for MCF-7). Transfection efficiencies were determined
using a β-Gal plasmid and were in the range of 10–20%.
Three independently derived and randomly chosen cell
clones were isolated.
Western blotting
Cell culture supernatant containing 0.1% FCS was col-
lected after 48 hours of culture and concentrated 20 times
by Biomax 5 k filter (Fa. Millipore, MA). Western blotting
was carried out according to manufacturer's instructions
utilizing the Novex gel system (Invitrogen, Germany) and
4–12% gradient SDS-PAGE. 12 μl of the concentrated
supernatants were applied and equal protein loading was
confirmed by Ponceau staining after transfer onto nitro-
cellulose membranes. Immunoreactive proteins were
detected by secondary antibody binding (donkey α-
(mouse IgG)) conjugated to horseradish peroxidase,
(1:50.000, Amersham Bioscience, Germany) followed by
incubation with ECL-Plus (0.1 ml/cm2, Amersham Bio-
sciences, Germany). The primary antibody, mouse anti-
ST-3 (Clone SL3.05, Neomarkers, CA) was used at a dilu-
tion of 1:300.
Proliferation assays
Cells of either three ST-3 or three mock clones were
detached by trypsin, counted and mixed in equal parts.
For each well, a total number of 4.5 × 104 cells (i.e. 1.5 ×
104 cells per clone) were mixed with 75 μl matrigel and
applied to matrigel coated 96-well plates. Gels were
allowed to solidify for 30 min at 37°C before supplemen-
tation with 100 μl of cell culture media. After 7 days of 3D
culture, cell numbers were determined by means of a MTS
assay (Fa. Promega, Germany). The applicability of the
MTS test was determined beforehand by confirming the
linearity of measurement of known cell numbers in 3D
cultures (data not shown). All assays were conducted at
least 3 times with triplicates.
In vivo tumourigenesis assay
8–12 week-old female immunocompromised NMRI
nude/nude mice were obtained from Harlan Winkelmann
(Borchem, Germany). 2 × 106 cells consisting of equal
parts of either three ST-3 or mock clones were mixed with
50 μl matrigel and injected into the mammary fat pad.
Growth factor depleted matrigel was prepared as
described by Taub et al [21]. Tumour take and tumour
growth was determined by the measurement of tumour
burdens estimated from calliper measurements twice a
week. The minimum tumour size was defined as 3 × 3
mm. Animals were sacrificed when tumours were larger
than 1000 mm3. Animals receiving MCF-7 tumour cells
were supplemented with 17-beta Estradiol pellets (IRA,
FI) that were implanted subcutaneously one week in
advance. Animals were sacrificed according to the guide-
lines of the "Deutsches Tierschutzgesetz".
Microarray gene expression analysis
Cells were grown for 3 days in 3D matrigel cultures as
described above. RNA-isolation was carried out using Tri-
Fast (peqLab, Erlangen, Germany). The integrity of resus-
pended total RNA was measured on a Bioanalyzer gel
(Agilent Technologies). For the microarray experiment,
500 ng of total RNA was reverse transcribed with an oligo-
(dT)-T7 promoter primer and Moloney murine leukemia
virus-reverse transcriptase (MMLV-RT) to synthesize first
and second strands of cDNA. Fluorescent antisense cRNA
was synthesized with simultaneous incorporation of
either cyanine 3-cytidine 5'-triphosphate (3-CTP) or cya-
nine 5-CTP. The labelling efficiency was verified with a
Nanodrop photometer (Kisker). Before hybridisation, 2
μg of each labelled cRNA product were fragmented and
mixed with control targets and hybridisation buffer
according to the supplier's protocol (Agilent Technolo-
gies). Hybridisations were done overnight for ~19 h at
60°C and arrays were subsequently washed. The scanning
resolution was 5-μm using a DNA microarray laser scan-
ner (Agilent). Experiments were then repeated, perform-
ing a colour swap dye reversal. Features were extracted
with an image analysis tool (Agilent Technologies, version
A 6.1.1) using default settings. Data analysis was con-
ducted on the Rosetta Inpharmatics Platform Resolver
Build version 4.0. Expression patterns were identified by
stringent data analysis using anticorrelation of the dye
reversal ratio profiles and a 2-fold expression cut-off.
Combining the first and the second criteria of analysis,
data points were filtered out with a low p value (p < 0.01).
To conduct functional categorizing, all genes with a mini-
mum of two-fold absolute changes were submitted to the
Database for Annotation, Visualization and Integrated
Discovery (DAVID[22]). Pathway mapping analysis for
these genes was done by BioRag (Bioresource for array
genes [23]).BMC Cancer 2007, 7:12 http://www.biomedcentral.com/1471-2407/7/12
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Statistical analysis
For all statistical analyses, a significance level of p ≤ 0.05
was employed. To test differences in means of cell num-
bers and tumour volumes, a two sided T-test was used.
Differences of tumour take curves were evaluated by
means of a log rank test. To conduct these statistical anal-
yses, the software package SPSS 12.0 was employed.
Results
Induction of ST-3 expression in co-cultures of breast 
epithelial cells and fibroblasts
The expression of ST-3 in fibroblasts of breast cancer tis-
sue was confirmed by co-staining with marker proteins for
fibroblasts and epithelial cells (Figure 1A). Epithelial cells
of both normal breast tissue and of IDC showed a low ST-
3 expression. Also fibroblasts surrounding normal ducts
expressed low amounts of ST-3, indicating a low level
basal expression of the protein. To determine in vitro,
whether ST-3 expression in fibroblasts is induced by epi-
thelial cells of different tumourigenic and invasive poten-
tial, the breast cancer cell lines MCF-7, MDA-MB-468 and
MDA-MB-231 and the non-tumourigenic, immortalized
cell line MCF-10A were co-cultured with primary breast
tumour fibroblasts (figure 1B). Fibroblasts were induced
to express endogenous ST-3 by all four cell lines at similar
levels, independently of their tumourigenic or invasive
properties. In accordance with the fibroblastoid appear-
ance of MDA-MB-231 cells, they were vimentin positive,
cytokeratin negative and showed low ST-3 expression (fig-
ure 1B and data not shown). The epithelial MCF-7 cells
displayed typical characteristics (epithelial morphology,
estrogen dependency and lack of caspase 3 activity, data
not shown) but did not stain positively for cytokeratin. As
the MCF-10A and MDA-MB-468 cells were both positive
for this marker, it is possible that the cells might have
acquired a mutation in the antigenic sequence not recog-
nized by the anti-cytokeratin antibody used.
Characterisation of ST-3 over-expressing clones
To investigate the functional consequences of such ST-3
over-expression, the non-invasive cell line MCF-7, as well
as the invasive cell line MDA-MB-231, were stable trans-
fected with ST-3. FISH analysis revealed a single copy inte-
gration of each of the ST-3 and mock transfected clones,
as well as their clonality (data not shown). Each separate
clone displayed a different site of integration. Western
blot analysis proved that the over-expressed ST-3 protein
displayed similar molecular weight patterns in MCF-7 and
MDA-MB-231 clones, corresponding to the published
molecular weight of ST-3 gene products (figure 2) [24].
Functional analysis in vivo
The tumourigenic potency of transfected cells was investi-
gated in an orthotopic xenograft model in nude mice. As
demonstrated in Figure 3, ST-3 over-expression in MDA-
MB-231 cells resulted in an elevated tumour take rate (p =
0.026). Mock transfected clones lead to a similar final
tumour take rate of 75%, but at a significantly delayed
time point. In addition, larger tumour volumes were
observed in ST-3 over-expressing MDA-MB-231 as well as
MCF-7 cells compared to mock transfected control cells in
the presence of complete matrigel (Figure 4A, p = 0.043 at
day 53; Figure 4C, p = 0.024 at day 30). In contrast, when
growth factor depleted matrigel was employed no differ-
ences between ST-3 and mock transfected cell clones were
detected (Figure 4B, p = 0.287 at day 53; Figure 4D, p =
0.373 at day 30). Tumour volume of ST-3 transfected and
control cells did not become significantly larger until day
39 for MDA-MB-231/ST-3 and day 23 for MCF-7/ST-3
after tumour cell injection. These data indicate that not
only the tumour settlement is enhanced by ST-3 over-
expression, but also the gain in tumour volume is acceler-
ated. This finding becomes obvious when the tumour vol-
ume is normalized to the day of occurrence instead of the
day of injection, so that the bias resulting from different
tumour takes are eliminated. Statistically significant
enhancement of tumour volume was achieved on day 18
for MDA-MB-231 clones (p = 0.028 and p = 0.422 for
complete and reduced martigel respectively) and on day
11 for MCF-7 clones (p = 0.034 and p = 0.309 for com-
plete and reduced matrigel respectively). These in vivo
experiments demonstrate that ST-3 causes similar effects
in MDA-MB-231 and MCF-7 cells by increasing the
tumour take as well as the tumour growth rate.
Analysis of cell proliferation in in vitro 3D matrigel 
cultures
To investigate the effect of ST-3 over-expression in vitro, a
3D matrigel model was established. The morphology of
ST-3 over-expressing clones and their corresponding con-
trol clones from MDA-MB-231 and MCF-7 was similar. In
general, cell clusters of ST-3 expressing cells appeared to
be larger in size (Figure 5A). To determine cell numbers, a
MTS test was employed and the linearity of measurement
of known cell numbers and OD490 nm was confirmed in
the 3D cultures (data not shown). Indeed, ST-3  over-
expressing cell clones showed a significantly higher cell
number compared with mock transfected control cells
(Figure 5B, MCF-7: 20.2% increase, MDA-MB-231: 23.2%
increase). This effect was not observed in standard 2D cul-
tures on cell culture dishes (data not shown). The addi-
tion of IGF-1 led to a further increase in the MDA-MB-
231/ST-3 cell number compared to mock transfected
clones. This difference was still present, but reduced by the
addition of IGF-1R inhibitor AG-538. In contrast, the
addition of AG-538 to MCF7/ST-3 and control cells, either
alone or in the presence of IGF-1, resulted in an equaliza-
tion of cell numbers in MCF-7/ST-3 and mock cells. These
data suggest that the activation of the IGF-1 signalling
pathway is required for ST-3 action in MCF-7 cells,BMC Cancer 2007, 7:12 http://www.biomedcentral.com/1471-2407/7/12
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whereas additional mechanisms seem to play a role in
MDA-MB-231 cells. The addition of apoptosis inhibitor Z-
VAD only slightly decreased the effect of ST-3 in MDA-
MB-231 clones and had no significant impact on MCF-7
cell clones.
Analysis of ST-3 influence on gene expression pattern
To investigate potential genes and pathways involved in
an ST-3 response apart from IGF-1R signalling, transcrip-
tional profiling of ST-3  over-expressing MDA-MB-231
cells in comparison to mock transfected cells was
employed. Of the total of 1190 significantly regulated
genes the overall number of genes induced by ST-3 was
larger than the number of genes that showed a down reg-
ulation (911 versus 279). In all, 708 differentially
expressed genes could be clustered according to their
involvement in biological processes by gene ontology
analysis resulting in 15 functional categories (Figure 6).
Fourteen of these categories, including signal transduc-
tion, cell proliferation, cell motility, and regulators of cell
metabolism revealed significant changes in expression (p
< 0.05, category "response to extracellular stimulus": p =
0.06; Figure 6). Examining the expression of MMP genes
revealed an up-regulation of MMP-28 in ST-3  over-
expressing cells (NM_032950, 2.9 fold). Up-regulation of
the ST-3 gene was not been detected at the mRNA level.
Since the enhanced protein production was clearly shown
by Western blotting (Figure 2), this was probably due to
technical reasons. Pathway mapping analyses showed the
following signalling pathways that were mainly affected:
the MAPK-signalling pathway, pathways involved in cell
cycle progression, Wnt-pathway, and the phosphatidyli-
nositol signalling system (Table 1). The expression of
small GTPases of the Rho family, RhoC and cdc42 were all
Induction of ST-3 expression in breast cancer fibroblast by breast epithelial cells Figure 1
Induction of ST-3 expression in breast cancer fibroblast by breast epithelial cells. A) Invasive ductal carcinoma 
(IDC) and normal breast tissue as well as B) co-cultures with different breast cell lines were stained by immunohistochemistry 
and immunocytochemistry, respectively. Similar expression patterns are observed in co-cultures and IDC tissue section. A tri-
ple staining of ST-3 (red), vimentin (turquoise) and E-cadherin (green) was performed and analysed by confocal microscopy. 
Nuclei were counterstained by DAPI. Original magnification: 630×.
MCF-10A
MCF-7
MDA-MB-468
MDA-MB-231
epithelial cells fibroblasts
Cytokeratin (green)
ST-3 (red)
Cytokeratin (green)
ST-3 (red)
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ST-3 (red) Vimentin (turquoise)
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control
B)
ST-3 (red)
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DAPI (blue) Vimentin (turquoise)
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up-regulated (2.4 and 5.7 fold) by ST-3 as well as the
adapter protein SHC3 (2.2 fold), which has been shown
to be involved in PI3-kinase activation promoting cell sur-
vival [25]. Transcripts coding for cell cycle regulators
required for G1/S transition, such as cyclin dependent
kinase 6 and 4 (CDK6, CDK4), CDK1 (also known as cell
division cycle 2, CDC2) and CyclinB (CCNB1) were up-
regulated, indicating a positive role for ST-3 during cell
cycle progression. A number of components of the MAPK
signalling pathway were also up-regulated (MAP4K2,
MAP4K1, MAP2K4) as well as PDGFRB (but not the IGF-
R1), which activates the MAPK- and the Akt pathways
indicating a role for growth factor mediated cellular
response. However, the MAPK pathway downstream tran-
scription factor AP-1 subunit jun (here v-jun sarcoma
virus 17 oncogene homologue, AC: BC002646) and
MAP3K2 were down regulated whereas a negative regula-
tor of cell cycle p27KIP1 (CDKN1B, cyclin dependent
kinase inhibitor1B) was up-regulated. ST-3 was also
found to up-regulate PKN2 (protein kinaseN2, also
known as PRK2) and the PI3-kinase catalytic subunit
p110 (PIK3CA). The latter is known to promote cell pro-
liferation via downstream activation of p70S6-kinase
[26]. PI3-kinase also leads to cell motility (via Rac1 acti-
vation) and cell survival (via Akt activation). Furthermore,
the anti-apoptotic Bcl-2, which was up-regulated 2.4 fold,
points towards a role for ST-3 in cell survival processes.
PKN2 was recently shown to be part of a ternary Rho/
PDK1 protein complex enhancing Akt activation in a PI3-
kinase dependent manner [27]. Components of the Wnt
ST-3 over-expression increases tumour take of MDA-MB- 231 cells in vivo Figure 3
ST-3 over-expression increases tumour take of MDA-
MB-231 cells in vivo. A pool of equal parts of three cell 
clones (total cell number: 2 × 106) was injected in 50 μl of a 
1:1 matrigel/PBS mixture into the mammary fatpad of nude 
mice. Tumour take was monitored twice a week. Groups 
included eight animals each. Stars indicate a p-value ≤ 0.05.
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Characterisation of ST-3 over-expressing cell clones Figure 2
Characterisation of ST-3 over-expressing cell clones. Conditioned media of ST-3 and mock transfected clones was ana-
lysed by Western blotting. Proform (~60 kDa), active form (~50 kDa) and degradation products (~35 kDa, ~28 kDa) are 
detected at similar amounts in ST-3 over-expressing clones of the cell lines MDA-MB-231 and MCF-7.
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signalling pathway, such as FZD7 (frizzled homologue7)
and its downstream target DVL3 (dishevelled, dsh) were
up-regulated. These genes are known to be involved in
tumour cell proliferation and invasion via activation of
the transcription factor TCF/LEF1. However, CTBP-1, an
inhibitor of this transcription factor, was up-regulated.
These results indicate that ST-3 activation induces synthe-
sis of intracellular signalling components characteristic
for downstream activation in response to growth factor
receptor activation, promoting cell cycle progression and
migration. Interestingly, no transcripts for soluble growth
factors (e.g. IGF) were induced by ST-3 over-expression.
Discussion
It has been shown in the present study that ST-3 induction
by an immortalized, non-tumourigenic cell line is similar
to the induction by tumourigenic breast cancer cell lines.
The stimulation of ST-3  expression in breast cancer
fibroblasts by different breast tumour cell lines was
recently described on mRNA and protein level and is in
line with our results [8,9]. Cell-cell contacts seem to be
beneficial, but not essential to induce ST-3 expression,
since ST-3 was induced in direct co-cultures and to a lower
extent in indirect co-cultures [8]. PKC seems to be
involved in the induction of ST-3 expression in normal
pulmonary fibroblasts by non-small cell lung cancer cells
[28]. The observation that non-tumourigenic cells are also
able to induce ST-3 expression might indicate that the
association of ST-3 expression and invasive properties of
carcinomas is a consequence of invasive epithelial cells
coming into contact with fibroblasts rather than being the
cause of invasion. The observation, both by our group as
well as others, that ST-3 over-expression does not lead to
an enhanced invasiveness of cells (data not shown and
[14]) provides further strength to this hypothesis. Normal
as well as tumor derived breast epithelial cells expressed
low amounts of ST-3. An epithelial expression of ST-3 was
already described in gastric and pancreatic carcinoma
[29,30] and seems to also occur in breast tissue.
ST-3 significantly enhanced tumour take as well as
tumour growth rates. Thus, the results indicate that ST-3 is
ST-3 induced increase of tumour volume is dependent on the presence of growth factors in vivo Figure 4
ST-3 induced increase of tumour volume is dependent on the presence of growth factors in vivo. Tumour volume 
in relation to the day of surgery is shown from A) MDA-MB-231 cell clones delivered with complete matrigel, B) MDA-MB-231 
cell clones applied in growth factor depleted matrigel, C) MCF-7 cell clones injected with complete matrigel and D) MCF-7 
cells applied with growth factor depleted matrigel. A pool of equal parts of three cell clones (total number: 2 × 106) was 
injected in a volume of 50 μl of (depleted) matrigel into the mammary fatpad of nude mice. Tumour volume was monitored 
twice a week. One week prior to MCF-7 cell transplantation, animals received oestrogen pellets subcutanously. Groups 
included eight animals each. Stars indicate a p-value ≤ 0.05.
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not only involved in tumour formation, as it was postu-
lated by previous studies [14], but additionally in tumour
progression. This was true for MCF-7, the breast cancer
cell line also used in former in vivo experiments [14,31],
and for MDA-MB-231 cells. MCF-7 is a rather well differ-
entiated tumour cell line, reflected by its oestrogen-
dependent growth. This cell line is non-invasive with
characteristics of epithelial cells (e.g. E-cadherin expres-
sion and a lack of ST-3 expression). In contrast, MDA-MB-
231 is a tumour cell line that has undergone epithelial-
mesenchymal transition and thus acquired fibroblastoid
characteristics (e.g. morphology, invasiveness, lack of E-
Cadherin and expression of low amounts of ST-3). MDA-
MB-231 cell growth is independent of the presence of oes-
trogen. Thus, ST-3 seems to have similar effects on breast
cancer cells derived from more differentiated tumours and
on cells from more aggressive and dedifferentiated
lesions.
The described in vitro results indicate that ST-3  over-
expression leads to an accelerated cell proliferation.
Indeed, ST-3 protein expression has been found to be up-
regulated in human invasive breast carcinomas and in co-
expression to clinically-used proliferation markers [32].
Since ST-3 has been shown to be capable of releasing IGF-
1 bound to IGFBP-1, thereby stimulating proliferation of
BAF/3 cells [11], this signalling pathway was investigated
in the present study. The IGF-1 signalling cascade seemed
to be the only or predominant pathway responsible for
the ST-3 effect in the MCF-7 cell line, possibly via the ERK/
MAPK pathway. It was described that ST-3 over-expres-
sion in MCF-7 cells results in the activation of p42/p44
ST-3 over-expression results in an increased cell number in vitro Figure 5
ST-3 over-expression results in an increased cell number in vitro. A) Cell morphology of representative clones of 
MDA-MB-231 and MCF-7 cells transfected with ST-3 expression plasmid or empty vector (mock) in 3D matrigel cultures. 
MDA-MB-231 clones show typical invasive structures, whereas MCF-7 cells formed rounded spheroids. Clusters appeared to 
be slightly larger in ST-3 transfected clones. Morphology seems not to be influenced by ST-3 over-expression. Original magnifi-
cation: 20×. B) OD 490 nm, which is proportional to cell numbers is shown for MDA-MB-231 and MCF-7 cell clones. A pool of 
equal parts of three clones was grown for 7 days in matrigel cultures with media containing 1% FCS with and without supple-
mentation of: AG-538 [100 μM], IGF-1 [50 ng/ml] and Z-VAD [50 μM]. Equal seeding for ST-3 and mock clones was confirmed 
at day 0. Stars represent significant differences in the cell number of mock and ST-3 transfected cells (p-value ≤ 0.05).
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MAP kinase [13]. In contrast, additional pathways seem to
be involved in MDA-MB-231 cells. In this respect, it is
notable that there seems to be cross-talk between IGF-1
and the estrogen receptor [33].
Transcriptional profiling revealed that cancer related proc-
esses such as cell proliferation, cell motility and cell
metabolism are affected by ST-3 over-expression. Most
notably, cell proliferation and cell cycle progression seem
to be influenced, an observation that has been confirmed
by our in vitro model. ST-3 leads to an up-regulation of the
small GTPases of the Rho family, RhoC and cdc42, which
have an important role in cancer progression, including
proliferation, invasion, and metastasis of breast tumours
[34]. Cdc42 and RhoC are induced in response to integrin
activation suggesting a role for ST-3 in mediating cell-
matrix adhesion, a prerequisite for cell migration. Rho
GTPases also play a role in the induction of MMP expres-
sion [35-37] and, conversely, blocking Rho function can
inhibit transcription of MMPs [38]. Whether this is also
true for ST-3 activated Rho GTPases still needs to be
proven. Interestingly, MMP-28 expression was induced in
ST-3 overexpressing cells. This MMP has been described to
be involved in EMT in lung carcinoma cells [39] and could
additionally contribute to the observed effect.
However, no induction of gene expression of growth fac-
tors could be detected in the presence of ST-3, suggesting
that ST-3 might not be involved in de novo growth factor
synthesis, which is crucial for autocrine activation of sig-
nalling pathways as a characteristic feature for tumour
cells [40]. Moreover, ST-3 seems to be involved in the
release and activation of soluble growth factors bound by
ECM components. This hypothesis is also supported by
our in vivo data and the finding that ST-3 can activate
extracellular IGF bound to IGFBP-1, which strengthened
its definition as a MMP [11]. Thus, our results suggest that
ST-3 enhances rather than initiates tumourigenesis by
either activating ECM-bound signaling components or at
least by synergistic effects with ECM containing growth
factors such as IGF-1. Our gene expression data also sup-
port a role in ST-3 activation of Wnt-signalling compo-
nents, such as FZD7 and DVL3, which is in line with the
activation of the Wnt pathway by ST-1/MMP-3 via E-cad-
ST-3 induced changes in expression pattern of MDA-MB-231 cells Figure 6
ST-3 induced changes in expression pattern of MDA-MB-231 cells. The pie diagram depicts gene distribution based on 
functional categories. Genes that were differentially expressed between ST-3 and mock clones at a minimum of twofold were 
included in the analysis.
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herin cleavage, resulting in EMT and thus enhanced inva-
sive properties of mammary tumour cells [41].
Conclusion
This study shows that ST-3 expression in fibroblasts is
induced not only by epithelial cells of tumour origin, but
also by non-transformed cells. Results from an orthotopic
in vivo model as well as from in vitro 3D assays have dem-
onstrated that ST-3 leads to an enhanced tumourigenic
potency in cell lines of different dedifferentiation status.
The mechanisms by which ST-3 exerts its function seem to
involve activation of IGF-1 signalling and potentially
MAPK and PI3-kinase pathways. Clearly, further studies
are needed to confirm and investigate the impact of ST-3
on these pathways, but our data provide some novel clues
for the mechanisms of ST-3 activation in breast cancer
cells.
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